82 FR 51433 - Notice Pursuant to the National Cooperative Research and Production Act of 1993-Medical Technology Enterprise Consortium
DEPARTMENT OF JUSTICE
Antitrust Division Federal Register Volume 82, Issue 213 (November 6, 2017)
Antitrust Division
Federal Register Volume 82, Issue 213 (November 6, 2017)
| Page Range | 51433-51433 | |
| FR Document | 2017-24101 |
[Federal Register Volume 82, Number 213 (Monday, November 6, 2017)] [Notices] [Page 51433] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2017-24101] [[Page 51433]] ======================================================================= ----------------------------------------------------------------------- DEPARTMENT OF JUSTICE Antitrust Division Notice Pursuant to the National Cooperative Research and Production Act of 1993--Medical Technology Enterprise Consortium Notice is hereby given that, on September 29, 2017, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. (``the Act''), Medical Technology Enterprise Consortium (``MTEC'') has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, 2C4 Technologies, Inc., San Antonio, TX; Actuated Medical, Inc., Bellefonte, PA; American Type Culture Collection (ATCC Federal Solutions), Manassas, VA; Amethyst Technologies, LLC, Baltimore, MD; Anu Life Sciences, Sunrise, FL; Arteriocyte, Inc. d/b/a/Compass Biomedical, Hopkinton, MA; Charles River Analytics, Inc., Cambridge, MA; Chimerix, Inc., Durham, NC; Cole Engineering Services, Inc., Orlando, FL; Corvid Technologies, Mooresville, NC; Daxor Corporation, New York, NY; Elemance, LLC, Clemmons, NC; Emergent BioSolutions, Gaithersburg, MD; Human Biomed, Inc., South Burlington, VT; L-3 Applied Technologies, Inc., San Diego, CA; LifeLink Foundation, Inc., Tampa, FL; MalarVx, Inc., Seattle, WA; Manzanita Pharmaceuticals, Inc., Woodside, CA; Medtronic, Minneapolis, MN; Melinta Therapeutics, Inc., New Haven, CT; Neuroplast BV, Maastricht, NETHERLANDS; Platelet BioGenesis, Inc., Boston, MA; RegeniSource LLC, San Antonio, TX; Remedor Biomed Ltd., Nazareth lllit, ISRAEL; Roccor, LLC, Longmont, CO; Soar Technology, Inc., Ann Arbor, MI; SynDaver Labs, Tampa, FL; The Board of Supervisors of Louisiana State University and Agricultural & Mechanical College herein represented by Louisiana State University Health Sciences Center in New Orleans (LSUHSC), New Orleans, LA; The Medical College of Wisconsin, Inc., Milwaukee, WI; The Metis Foundation, San Antonio, TX; University of Iowa, Iowa city, IA; University of Maryland, College Park, MD; Vcom3D, Inc., Orlando, FL, and Vivacelle Bio, Inc., Chicago, IL have been added as parties to this venture. Also, Applied Medical Device Institute (aMDI)--Grand Valley State University, Grand Rapids, MI; Aptus, LLC, Clemson, SC; Ellipsis Technologies, Inc., Greenville, SC; Johns Hopkins University, Baltimore, MD; Longeveron LLC, Miami, FL; Lovelace Biomedical and Environmental Research Institute, Albuquerque, NM; MicroCures, Inc., Santa Cruz, CA; New York Institute of Technology, Old Westbury, NY; NGT-VC 2012 Limited Partnership (NGT3), Nazareth, ISRAEL; and Otologic Pharmaceutics Inc., Oklahoma City, OK, have withdrawn as parties to this venture. No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and MTEC intends to file additional written notifications disclosing all changes in membership. On May 9, 2014, MTEC filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the Federal Register pursuant to Section 6(b) of the Act on June 9, 2014 (79 FR 32999). The last notification was filed with the Department on June 23, 2017. A notice was published in the Federal Register pursuant to Section 6(b) of the Act on August 15, 2017(82 FR 38708). Patricia A. Brink, Director of Civil Enforcement, Antitrust Division. [FR Doc. 2017-24101 Filed 11-3-17; 8:45 am] BILLING CODE P
![Federal Register / Vol. 82, No. 213 / Monday, November 6, 2017 / Notices 51433
DEPARTMENT OF JUSTICE Also, Applied Medical Device Registration No. FC3015915, at the
Institute (aMDI)—Grand Valley State registered address of 8119 Court
Antitrust Division University, Grand Rapids, MI; Aptus, Avenue, Hamlin, West Virginia. Id. at 1.
LLC, Clemson, SC; Ellipsis The Order alleged that this registration
Notice Pursuant to the National Technologies, Inc., Greenville, SC; Johns was due to expire on August 31, 2017.
Cooperative Research and Production Hopkins University, Baltimore, MD; Id.
Act of 1993—Medical Technology Longeveron LLC, Miami, FL; Lovelace
Enterprise Consortium As to the substantive grounds for the
Biomedical and Environmental
Research Institute, Albuquerque, NM; proceeding, the Show Cause Order
Notice is hereby given that, on alleged that Registrant is owned by
September 29, 2017, pursuant to Section MicroCures, Inc., Santa Cruz, CA; New
York Institute of Technology, Old George ‘‘Chip’’ Chapman and Summer
6(a) of the National Cooperative
Westbury, NY; NGT–VC 2012 Limited Chapman, and that George Chapman is
Research and Production Act of 1993,
Partnership (NGT3), Nazareth, ISRAEL; Registrant’s Pharmacist-in-Charge (PIC).
15 U.S.C. 4301 et seq. (‘‘the Act’’),
Medical Technology Enterprise and Otologic Pharmaceutics Inc., Id. The Show Cause Order alleged that
Consortium (‘‘MTEC’’) has filed written Oklahoma City, OK, have withdrawn as on June 30, 2016, DEA executed an
notifications simultaneously with the parties to this venture. Administrative Inspection Warrant
Attorney General and the Federal Trade No other changes have been made in (AIW) at Registrant based on ‘‘tips that
Commission disclosing changes in its either the membership or planned PIC Chapman was frequently impaired
membership. The notifications were activity of the group research project. and was unlawfully removing
filed for the purpose of extending the Membership in this group research controlled substances from the
Act’s provisions limiting the recovery of project remains open, and MTEC pharmacy.’’ Id. at 2. The Order then
antitrust plaintiffs to actual damages intends to file additional written alleged that during the inspection, DEA
under specified circumstances. notifications disclosing all changes in personnel interviewed PIC Chapman
Specifically, 2C4 Technologies, Inc., membership. and other pharmacy employees. Id.
San Antonio, TX; Actuated Medical, On May 9, 2014, MTEC filed its
original notification pursuant to Section With respect to the interview of PIC
Inc., Bellefonte, PA; American Type Chapman, the Show Cause Order
Culture Collection (ATCC Federal 6(a) of the Act. The Department of
Justice published a notice in the Federal alleged that he made various material
Solutions), Manassas, VA; Amethyst false statements to the Investigators. Id.
Technologies, LLC, Baltimore, MD; Anu Register pursuant to Section 6(b) of the
Act on June 9, 2014 (79 FR 32999). These included minimizing the quantity
Life Sciences, Sunrise, FL; Arteriocyte, of oxycodone and hydrocodone that had
The last notification was filed with
Inc. d/b/a/Compass Biomedical,
the Department on June 23, 2017. A been lost ‘‘in the last year,’’ stating that
Hopkinton, MA; Charles River
notice was published in the Federal he had failed to reported all but one of
Analytics, Inc., Cambridge, MA;
Register pursuant to Section 6(b) of the the instances in which these drugs were
Chimerix, Inc., Durham, NC; Cole
Act on August 15, 2017(82 FR 38708). ‘‘lost’’ because they were ‘‘‘not
Engineering Services, Inc., Orlando, FL;
Corvid Technologies, Mooresville, NC; significant’ losses,’’ by denying that he
Patricia A. Brink,
Daxor Corporation, New York, NY; knew ‘‘anything further about the nature
Director of Civil Enforcement, Antitrust
Elemance, LLC, Clemmons, NC; Division. of the pharmacy’s losses’’ while
Emergent BioSolutions, Gaithersburg, [FR Doc. 2017–24101 Filed 11–3–17; 8:45 am]
‘‘claim[ing] that he was not abusing
MD; Human Biomed, Inc., South prescriptions drugs,’’ and stating ‘‘that
BILLING CODE P
Burlington, VT; L–3 Applied many of his per diem or fill-in
Technologies, Inc., San Diego, CA; pharmacists were previous drug
LifeLink Foundation, Inc., Tampa, FL; DEPARTMENT OF JUSTICE abusers.’’ Id.
MalarVx, Inc., Seattle, WA; Manzanita The Show Cause Order then alleged
Pharmaceuticals, Inc., Woodside, CA; Drug Enforcement Administration that in a subsequent interview
Medtronic, Minneapolis, MN; Melinta conducted on July 22, 2016, Chapman
Therapeutics, Inc., New Haven, CT; ChipRX, L.L.C., d/b/a City Center
Pharmacy; Decision and Order ‘‘admitted that during the past year, he
Neuroplast BV, Maastricht, diverted oxycodone or hydrocodone
NETHERLANDS; Platelet BioGenesis, On August 19, 2016, the former pills equivalent to ‘200–300 mg every
Inc., Boston, MA; RegeniSource LLC, Acting Administrator issued an Order to day,’ a total of approximately 25,000
San Antonio, TX; Remedor Biomed Ltd., Show Cause and Immediate Suspension pills.’’ Id. at 3. The Order also alleged
Nazareth lllit, ISRAEL; Roccor, LLC, of Registration to ChipRX, L.L.C., d/b/a that ‘‘Chapman admitted that he
Longmont, CO; Soar Technology, Inc., City Center Pharmacy (hereinafter, routinely falsified inventory records’’
Ann Arbor, MI; SynDaver Labs, Tampa, Registrant), of Hamlin, West Virginia. and that he ‘‘shredded invoice and
FL; The Board of Supervisors of The Show Cause Order proposed the supplier records, including DEA 222
Louisiana State University and revocation of Registrant’s DEA forms and electronic Controlled
Agricultural & Mechanical College Certificate of Registration and the denial Substances Ordering System (‘CSOS’)
herein represented by Louisiana State of any pending application to renew or records.’’ Id. The Order further alleged
University Health Sciences Center in modify its registration, on the ground
New Orleans (LSUHSC), New Orleans, that ‘‘Chapman admitted that he had
that its ‘‘continued registration is
relapsed,’’ and told ‘‘DEA [I]nvestigators
Pmangrum on DSK3GDR082PROD with NOTICES
LA; The Medical College of Wisconsin, inconsistent with the public interest.’’
Inc., Milwaukee, WI; The Metis that he ‘couldn’t wait’ for’’ the
Show Cause Order, at 1 (citing 21 U.S.C.
Foundation, San Antonio, TX; 824(a)(4) and 823(f)). expiration of the Memorandum of
University of Iowa, Iowa city, IA; As to the Agency’s jurisdiction, the Agreement (MOA) which he had
University of Maryland, College Park, Show Cause Order alleged that previously entered into with the Agency
MD; Vcom3D, Inc., Orlando, FL, and Registrant is registered as a pharmacy ‘‘so he could begin diverting . . . drugs
Vivacelle Bio, Inc., Chicago, IL have with authority to dispense schedule II– to feed his addiction.’’ Id. The Order
been added as parties to this venture. V controlled substances under then alleged that Chapman admitted to
VerDate Sep<11>2014 14:48 Nov 03, 2017 Jkt 244001 PO 00000 Frm 00050 Fmt 4703 Sfmt 4703 E:\FR\FM\06NON1.SGM 06NON1](https://thefederalregister.org/doc/82_FR_51646/page/1.svg)
Document Created: 2017-11-07 10:30:57
Document Modified: 2017-11-07 10:30:57
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| FR Citation | 82 FR 51433 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR